Moderna CEO Says mRNA Tech Shifting Healthcare Toward Personalization

Stéphane Bancel, the CEO of Moderna, said mRNA technology is transforming healthcare by moving away from a one-size-fits-all medical model ^[1].

This shift represents a fundamental change in how diseases are treated. By leveraging the speed of mRNA development, medicine can move toward personalized therapies tailored to an individual's specific genetic makeup rather than relying on broad population averages.

Speaking on the McKinsey Podcast with Eric Kutcher, Bancel said the rapid development of COVID-19 vaccines served as a catalyst for this evolution ^[1]. The infrastructure and knowledge gained during the pandemic are now being applied to more complex medical challenges. Specifically, the technology is enabling the creation of new treatments for rare genetic diseases and individualized cancer therapies ^[1].

This move toward precision medicine coincides with a broader technological surge in the industry. Healthcare AI spending reached $1.4 billion in 2025, which was nearly triple the investment seen in 2024 ^[2]. The integration of AI and mRNA allows for faster identification of genetic targets and more precise delivery of therapeutic instructions to cells.

These innovations arrive as the global health system faces significant labor pressures. Projections indicate a global health-worker shortfall of approximately 11 million by 2030 ^[3]. The adoption of personalized, tech-driven treatments may help optimize patient outcomes and reduce the burden on exhausted medical staff by increasing the efficacy of first-line treatments.

Bancel said the ability to program medicine like software allows for a level of agility previously unseen in pharmacology ^[1]. Instead of developing a single drug for millions of people, the industry is moving toward a model where the treatment is designed for the specific patient.